Europe Over three decades at Terumo, Takuya Hosogai has seen the Group evolve across businesses, markets and technologies. Now leading Terumo Europe, he discusses the region’s growing role in Pharmaceutical Solutions alongside its established interventional business, and how closer pharma partnerships, continuous innovation and a deeply rooted culture are shaping its…
Belgium The latest stories from healthcare and the life sciences in Belgium, the Netherlands and Luxembourg (BeNeLux). UCB is considering a USD five billion investment in the US to avoid President Trump’s tariffs on the EU; Belgium’s competition authority fines three consumer healthcare companies; and the launch of a EUR 200…
Spain Brazilian national Maria Fernanda Prado, who began her career in pharma more than 20 years ago, has been at Janssen/Johnson & Johnson for more than half of that time. She has taken on the leadership of a diverse set of geographies — from Turkey to Central Europe and Benelux —…
Belgium Belgium, one of Europe’s most important countries for biopharmaceutical production and R&D, assumed presidency of the Council of the European Union on the first of January. As part of its Presidency Programme, Belgium has highlighted health as one of its 14 focus areas, with the hope of strengthening the three…
Global UCB has been undergoing a far-reaching digital business transformation, integrating novel approaches across its R&D organisation, including Computer-Aided Drug Design (CADD) and AI, while striving to maintain a patient-centric focus. Speaking at the recent FT Global Pharma and Biotech Summit, CEO Jean-Christophe Tellier discussed the Belgian midcap’s digital undertakings and…
Global Amgen has forged a solid position as one of the world’s largest independent biotechnology companies. With a market capitalisation of some USD 130 billion and 27 approved medicines, the US-based firm has come a long way from its original biotech upstart status in 1980. Nonetheless, Amgen has faced obstacles in…
Belgium Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities to develop, manufacture and sell medicines. Despite representing only a mid-size marketplace from an in-country commercial perspective, the comparatively…
Belgium Janssen has the lofty aim of reaching USD 60bn dollars in sales by 2025, an 8bn increase on the 2021 figure, despite some high-profile losses of exclusivity and the spin-off of its consumer healthcare branch. This massive growth plan involves both existing products as well as new CAR-T and autoimmune…
Belgium There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from Abbott, the American drugmaker faced a less happy turning point as its leading drug Humira came up against stiff competition…
Belgium Representatives of Belgian associations for innovative pharma, generics and biosimilars, medtech, OTC, biotech, hospitals, and medical professionals share their key agenda priorities. These include where they feel that change is needed to drive better outcomes for their members as well as for the overall healthcare ecosystem. Innovative Pharma: Building…
Belgium Germany and Belgium have long held an important trading relationship, says Margit Kunz of AHK Debelux, the German chamber of commerce in Belgium and Luxembourg. She outlines some of the key industrial investments and trends for German companies within Belux and why Belgium should be better known as an investment…
Belgium Perhaps to the surprise of many, Belgium is the world’s second-largest producer of vaccines, behind only the US, and – capitalising on its years of experience in the field – played a vital role in the development, production, and distribution of COVID-19 vaccines over the past three years. An ecosystem…
See our Cookie Privacy Policy Here
